Prediction Case File
YouTubeEvaluation Complete

Friends! In this video, I'm going to do a Broadcom stock analysis & discuss the risks and upside potential of AVGO stock

1 extracted signal · 1 resolved · 0 still active

The Patient Investor profile imageThe Patient InvestorIndependent analyst profile
Source published
20 Dec 2025, 00:21 UTC
Recorded by Tahlil Plus
18 May 2026, 20:23 UTC
Video preview for Friends! In this video, I'm going to do a Broadcom stock analysis & discuss the risks and upside potential of AVGO stock
Source overview

AI-generated source summary

Broadcom (AVGO) has shown strong revenue growth through acquisitions, with a current price of $329.88. Analysts expect AI chip sales to double, contributing significantly to revenue. The stock's forward P/E ratio is 69, with a 5-year target price of $613.55, suggesting an 89% upside. Oracle (ORCL) faces a more challenging financial situation with high debt and negative free cash flow. The stock is trading at $180.03, down 18% in the past month. Its forward P/E is around 22, significantly lower than AVGO, indicating potential overvaluation concerns, with a price target around $280 for a double in 5 years. However, the current valuation might be fair rather than undervalued.

AI-generated summary based on the source content.

Live evaluation

Signal outcomes at a glance

Evaluation Complete
Signals
1
Extracted from this source
Open
0
Still being tracked
Successful
0
Resolved successfully
Failed
1
Resolved unsuccessfully
Other
0
Cancelled, invalid or excluded
Resolved success
0%
1 resolved; open signals omitted
Extracted intelligence

Signals in this source

Case timeline

Evidence and evaluation progress

  1. Original source published

    The analyst published the original source item.

  2. First prediction resolved

    The first evaluable outcome in this case reached a terminal result.

  3. Case evaluation completed

    All evaluable predictions in this case reached terminal outcomes.

  4. Source recorded by Tahlil Plus

    The public source was preserved as the evidence record for this case.

  5. Market predictions extracted

    1 eligible signal linked to this case.

  6. Outcome tracking started

    Tahlil Plus began monitoring the extracted predictions.

Analyst snapshot

The Patient Investor

Platform-wide history, separate from this source evaluation.

Reliability
47.9
Tracked signals
355
Historical success
34.9%
View full analyst profile →
Methodology & disclosure

Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.

Continue the evidence trail